Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Doccole on May 25, 2022 7:14am

Significance

Any significance to the corporate shakeup?
Comment by MrMugsy on May 25, 2022 7:52am
Yes - I think the shuffle is now needed - entering a new corporate phase. Since Bloom Burton, Dan was really positive on all fronts.  He focused on Hoffman for his background in US Capital markets.  I think that's the significance going forward (and Hoffman's pain background). The goal is to be the name-of-the-game in the operating room - and - it seems easy enough for OTENA ...more  
Comment by Doccole on May 25, 2022 8:36pm
Are we going to Nasdq before the start of phase 2? will we get fast tracked with our 2nd drug? What will be the next news drop!?
Comment by MrMugsy on May 25, 2022 11:17pm
Likely not before P2 but after P2 and during negotiations ... depends on a few things but that would be my best guess at this time. Our new Board Chairman knows all about fast-track and breakthrough therapy at Heron.  They got both through the FDA.  I am assuming we will take the dosing and regimen data we are presently collecting and make a submission after that is available. Tough to ...more  
Comment by Banana1234 on May 25, 2022 1:48pm
They haven't gotten rid of Dan yet, so the problem still exists. Changing up the incompetent board isn't a bad thing, but as long Dan remains at the helm this company will be fighting headwinds. He's incompetent and a liar.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities